Charles S. Berkman
2016 - Ligand Pharmaceuticals
In 2016, Charles S. Berkman earned a total compensation of $1.3M as Vice President and General Counsel at Ligand Pharmaceuticals, a 11% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $136,350 |
|---|---|
| Option Awards | $452,035 |
| Salary | $329,167 |
| Stock Awards | $376,275 |
| Other | $6,343 |
| Total | $1,300,170 |
Berkman received $452K in option awards, accounting for 35% of the total pay in 2016.
Berkman also received $136.4K in non-equity incentive plan, $329.2K in salary, $376.3K in stock awards and $6.3K in other compensation.
Rankings
In 2016, Charles S. Berkman's compensation ranked 6,961st out of 14,075 executives tracked by ExecPay. In other words, Berkman earned more than 50.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,961 out of 14,075 | 51st |
Division Manufacturing | 2,614 out of 5,486 | 52nd |
Major group Chemicals And Allied Products | 854 out of 1,900 | 55th |
Industry group Drugs | 657 out of 1,543 | 57th |
Industry Pharmaceutical Preparations | 521 out of 1,173 | 56th |
Source: SEC filing on April 14, 2017.
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2016.